PT1206474E - Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2 - Google Patents
Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2Info
- Publication number
- PT1206474E PT1206474E PT00955867T PT00955867T PT1206474E PT 1206474 E PT1206474 E PT 1206474E PT 00955867 T PT00955867 T PT 00955867T PT 00955867 T PT00955867 T PT 00955867T PT 1206474 E PT1206474 E PT 1206474E
- Authority
- PT
- Portugal
- Prior art keywords
- sulfonylphenylpirazole
- cox
- inhibitors
- compounds
- cyclooxygenase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38495499A | 1999-08-27 | 1999-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1206474E true PT1206474E (pt) | 2004-10-29 |
Family
ID=23519433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT00955867T PT1206474E (pt) | 1999-08-27 | 2000-08-24 | Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1206474B1 (pt) |
JP (1) | JP2003508401A (pt) |
AT (1) | ATE267830T1 (pt) |
CA (1) | CA2379421A1 (pt) |
DE (1) | DE60011100T2 (pt) |
DK (1) | DK1206474T3 (pt) |
ES (1) | ES2222919T3 (pt) |
MX (1) | MXPA02002111A (pt) |
PT (1) | PT1206474E (pt) |
WO (1) | WO2001016138A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2166710B1 (es) * | 2000-04-25 | 2004-10-16 | J. URIACH & CIA, S.A. | Nuevos compuestos heterociclicos con actividad antiinflamatoria. |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
UA76461C2 (en) * | 2001-05-24 | 2006-08-15 | Lilly Co Eli | Pyrrazole derivatives as pharmaceutical agents, use thereof, a pharmaceutical composition on their basis |
KR100478467B1 (ko) * | 2002-06-24 | 2005-03-23 | 씨제이 주식회사 | 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물 |
KR101050700B1 (ko) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
ATE355839T1 (de) * | 2002-09-09 | 2007-03-15 | Amgen Inc | 1,4,5-substituierte 1,2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivate als tnf-alpha und interleukin senkende wirkstoffe zur behandlung von entzündungen |
UA80571C2 (en) * | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
AU2003291642A1 (en) * | 2002-11-22 | 2004-06-18 | Eli Lilly And Company | Pyrazoloazepine compounds as pharmaceutical agents |
WO2007140439A2 (en) | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2008121558A1 (en) | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP2010527929A (ja) | 2007-05-18 | 2010-08-19 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8859596B2 (en) | 2008-09-16 | 2014-10-14 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
US8377945B2 (en) * | 2009-06-15 | 2013-02-19 | Rigel Pharmaceuticals Inc. | Small molecule inhibitors of spleen tyrosine kinase (SYK) |
JP2013518085A (ja) * | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体 |
JP6042896B2 (ja) | 2011-10-06 | 2016-12-14 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 殺菌剤としての複素環ピリ(ミ)ジニルピラゾール |
CN104302640A (zh) | 2012-03-16 | 2015-01-21 | 埃克希金医药品有限公司 | 3,5-二氨基吡唑激酶抑制剂 |
ES2619125T3 (es) | 2013-04-25 | 2017-06-23 | Beigene, Ltd. | Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa |
CN103232394B (zh) * | 2013-05-14 | 2014-09-24 | 浙江医药高等专科学校 | 含吡唑类化合物、其制备方法和用途 |
JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗pd−1抗体並びにその治療及び診断のための使用 |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
JP6526189B2 (ja) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗pd−l1抗体並びにその治療及び診断のための使用 |
MY191736A (en) | 2014-12-23 | 2022-07-13 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
CN109563099B (zh) | 2016-08-16 | 2023-02-03 | 百济神州有限公司 | 一种化合物的晶型、其制备和用途 |
AU2017313085A1 (en) | 2016-08-19 | 2019-03-14 | Beigene Switzerland Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
BR112019022383A2 (pt) | 2017-04-27 | 2020-05-19 | Bayer Animal Health Gmbh | novos derivados de pirazol bicíclico |
CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4824834A (en) * | 1986-10-31 | 1989-04-25 | Otsuka Pharmaceutical Company, Limited | Pyrazolotriazine compounds |
JP2691317B2 (ja) * | 1989-08-25 | 1997-12-17 | 株式会社大塚製薬工場 | 4―ヒドロキシ―8―(3―低級アルコキシ―4―フェニルスルフィニルフェニル)ピラゾロ〔1,5―a〕―1,3,5―トリアジン光学活性体の塩類及びその製造方法 |
JP2665564B2 (ja) * | 1989-08-25 | 1997-10-22 | 株式会社大塚製薬工場 | 細胞防護剤 |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
JPH07118272A (ja) * | 1993-10-19 | 1995-05-09 | Otsuka Pharmaceut Co Ltd | 4−ヒドロキシピラゾロトリアジン誘導体およびその光学活性体の製造方法 |
US5401765A (en) * | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
AU3815495A (en) * | 1994-11-08 | 1996-05-31 | Eisai Co. Ltd. | Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects |
GB9422667D0 (en) * | 1994-11-10 | 1995-01-04 | Zeneca Ltd | Herbicides |
GB9520584D0 (en) * | 1995-10-09 | 1995-12-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
JPH10310578A (ja) * | 1996-11-13 | 1998-11-24 | Yoshitomi Pharmaceut Ind Ltd | 3−フェニルピラゾール化合物 |
-
2000
- 2000-08-24 CA CA002379421A patent/CA2379421A1/en not_active Abandoned
- 2000-08-24 JP JP2001519704A patent/JP2003508401A/ja not_active Withdrawn
- 2000-08-24 WO PCT/US2000/023214 patent/WO2001016138A1/en active IP Right Grant
- 2000-08-24 MX MXPA02002111A patent/MXPA02002111A/es not_active Application Discontinuation
- 2000-08-24 ES ES00955867T patent/ES2222919T3/es not_active Expired - Lifetime
- 2000-08-24 DK DK00955867T patent/DK1206474T3/da active
- 2000-08-24 DE DE60011100T patent/DE60011100T2/de not_active Expired - Fee Related
- 2000-08-24 PT PT00955867T patent/PT1206474E/pt unknown
- 2000-08-24 EP EP00955867A patent/EP1206474B1/en not_active Expired - Lifetime
- 2000-08-24 AT AT00955867T patent/ATE267830T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1206474A1 (en) | 2002-05-22 |
DK1206474T3 (da) | 2004-10-04 |
EP1206474B1 (en) | 2004-05-26 |
DE60011100D1 (de) | 2004-07-01 |
CA2379421A1 (en) | 2001-03-08 |
WO2001016138A1 (en) | 2001-03-08 |
JP2003508401A (ja) | 2003-03-04 |
ES2222919T3 (es) | 2005-02-16 |
DE60011100T2 (de) | 2005-06-16 |
MXPA02002111A (es) | 2002-10-31 |
ATE267830T1 (de) | 2004-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1206474E (pt) | Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2 | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
NO20032254L (no) | Forbindelser for inhibering av ekspresjon av VACM-I | |
DE602004024909D1 (de) | Platinkomplexe zur behandlung von tumoren | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
NO20061122L (no) | 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer | |
PT1109799E (pt) | Derivados de 4,5-diaril-3(2h)-furanona como inibidores da ciclooxigenase-2 | |
ES2171723T3 (es) | 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2. | |
ATE408601T1 (de) | Fredericamycin-derivate | |
UA85559C2 (en) | Aminobenzophenone compounds | |
DE60234760D1 (de) | Phenylindole zur behandlung von hiv | |
DE602004020070D1 (de) | Thienopyrimidin-derivate als kaliumkanal-inhibitoren | |
ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
DE60129330D1 (de) | Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids | |
DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
SE0302304D0 (sv) | Novel compounds | |
WO2005007123A3 (en) | Pin1-modulating compounds and methods of use thereof | |
ES2147973T3 (es) | Estirenos alquilatados como profarmacos de inhibidores de cox-2. | |
ES2182035T3 (es) | Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa. | |
DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
NO20005548L (no) | Mykobakterieinhibitorer |